The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness
…
Q: Where did you grow up?
Minneapolis, MN
Q: Where did you go to college/graduate school?
I received my undergraduate degree received from University of
…
Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.
Earlier
…
340B covered entity allies in the U.S. House are booking an hour of floor speeches by members lauding the drug discount program next week Tuesday after all legislative business is finished.
Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.) are
…SPONSORED CONTENT
Drastic federal cuts to the 340B program. Alarming changes to Gilead’s Advancing Access Program. If your organization is a federal grantee or health system providing HIV care and/or prevention services, you know there has never been a more important time to future-proof your program—while still offering the highest standards of compassionate care.
What’s more, how entities provide care to their communities is quickly changing. Per CDC guidelines, providers are encouraged to prescribe PrEP to any patient who asks for it, and to have conversations about PrEP with all sexually active adolescent and adult patients. Telehealth is making care more accessible to rural communities, as well as eliminating some of the barriers and fears for patients who don’t feel comfortable in traditional health care settings.
What does all that mean for covered entities? It means the landscape is changing quickly, and there is an urgent need to consider the entire health care journey of all your patients, both those who
…
Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.
Real Chemistry, a health sector communications consulting firm, published
…
Drug industry technology company Kalderos, which has struggled to launch its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate instead of as an up-front discount, has a new chief executive officer.
The company announced
…
340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.
The U.S.
…
For the first time since the 340B contract pharmacy impasse started over a year and a half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal
…
A federal district judge on Friday granted the federal government’s motion to stay proceedings in drug industry vendor Kalderos’ 340B contract pharmacy suit.
The government had asked U.S. District Judge Dabney Friedrich of the District of Columbia to pause Kalderos’
…*Sign up for news summaries and alerts from 340B Report
